Top 7 Research Reports For July 11, 2016
Zacks Investment Research | Jul 11, 2016 01:50AM ET
Monday, July 11, 2016
We are featuring 16 research reports from our analyst team in today's Zacks Research Daily, including reports on Gilead (GILD), Altria (MO), Qualcomm (NASDAQ:QCOM) (QCOM) and Pfizer (NYSE:PFE) (PFE).
Gilead shares have turned around a bit in recent days, but still still lag the broader market in the year-to-date period on continued negative sentiment on the biotech space as a whole. These clouds notwithstanding, the covering analyst likes this Zacks Rank # 2 (Buy) rated stock for its strong HIV and HCV portfolio and robust product pipeline, which could get further boost from deals that the company has plenty of financial firepower to execute. (You can here .)
Zacks Rank # 2 (Buy) rated Altria shares are up an impressive +19% year-to-date, likely reflecting the low-beta tobacco giant's stable business outlook and attractive dividend (currently yielding a juicy 3.2%). The analyst likes the company's strong portfolio of tobacco and wine products and its ability to adapt to evolving demands, such as developing several non combustible tobacco products. (You can here .)
The analyst likes the buy-rated Qualcomm stock for its leadership position in the global wireless baseband chipset market and its growing presence in related opportunities such as mobile computing and IoT. The company's new patent license agreements with Chinese smartphone makers should boost Qualcomm’s top line and also solidify its footing in the Chinese market (You can here .)
Other noteworthy reports we are featuring today include Procter & Gamble (PG), Novartis (NVS) and Southern Company (NYSE:SO) (SO).
- .
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include .
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst thinks Southern Company will provide cleaner energy to its customers through this move.
Strong Old Navy performance, which gained from favorable Memorial Day shift, drove Gap's June comps and helped it revive from its long negative comps streak.
The Zacks analyst believes the company has earned its S&P 500 membership on the back of consistent performance and several strategic initiatives.
The covering analyst believes cost savings, the Hospira buy and strong performance of new products will drive Pfizer's performance.
The covering analyst believes that focus on cost containment and inventory management has kept LB afloat in a soft consumer environment.
The Zacks analyst thinks expansion plans will drive growth and conversion to fee-based contracts will boost earnings.
Mohawk has heavy domestic exposure and revenues are expected to increase as the sector gains further momentum.
New Upgrades/h6
DGX has experienced upward estimate revisions ahead of Q2 earnings and the Zacks analyst thinks team-ups with Safeway and HealthOne are upsides.
The Zacks analyst believes that besides a solid oncology portfolio, Novartis' expanding immuno-oncology portfolio and biosimilars pipeline should boost growth prospects.
Stericycle's network is not just the largest in the industry, it is difficult to replicate and allows it to compete on both service and price, according to the covering analyst.
New Downgrades/h6
The Zacks analyst thinks that though P&G has stepped up innovation and marketing investments to boost sales, these efforts will take time to yield results.
The covering analyst remains cautious regarding weakness in iPhone demand since competitor Samsung has upgraded its second-quarter 2016 earnings guidance citing robust smartphone sales.
The Zacks analyst believes margin pressure remains a concern due to slow rise in interest rates while muted growth in net interest income remains a headwind.
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.Get The AppZacks Investment Research
Written By: Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.